Gynecologic Cancer

Top Story

Combination demonstrates activity in endometrial cancer

June 21, 2017

CHICAGO — The combination of lenvatinib and pembrolizumab conferred benefit to previously treated patients with metastatic endometrial cancer, according to study results presented at the ASCO Annual Meeting.

Researchers reported no additional safety concerns beyond what had been observed in prior studies of each agent, and toxicities were managed with dose modification or interruption.

In the Journals Plus

Researchers define cancer risk in BRCA1/BRCA2 carriers

June 20, 2017
Women with BRCA1 mutations were more likely to develop breast cancer, ovarian cancer and contralateral breast cancer, and at earlier ages, than with women with…
In the Journals Plus

Tumor marker associated with poor ovarian cancer outcomes

June 19, 2017
Women with advanced ovarian cancer who expressed the tumor antigen

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist, also will serve as…
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Video
Meeting News Coverage

VIDEO: Combination therapies may improve response to checkpoint inhibitors

June 5, 2016
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Meeting News

Combination demonstrates activity in endometrial cancer

June 21, 2017
CHICAGO — The combination of lenvatinib and pembrolizumab conferred benefit to previously treated patients with metastatic endometrial cancer…

In the Journals Plus

Researchers define cancer risk in BRCA1/BRCA2 carriers

June 20, 2017
Women with BRCA1 mutations were more likely to develop breast cancer, ovarian cancer and contralateral breast cancer, and at earlier ages, than with…

In the Journals Plus

Tumor marker associated with poor ovarian cancer outcomes

June 19, 2017
Women with advanced ovarian cancer who expressed the tumor antigen

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

Meeting NewsVideo

VIDEO: Speaker discusses how studies may impact future of gynecologic oncology

June 17, 2017
CHICAGO — Michael J. Birrer, MD, PhD, director of University of Alabama at Birmingham Comprehensive Cancer Center as of Aug. 1 who currently…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

Oral contraceptive use does not increase long-term cancer risk

June 14, 2017
Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General…

In the Journals

Nearly 1 in 3 people worldwide overweight or obese

June 13, 2017
More than 2 billion children and adults globally were affected by excess weight in 2015, and the percentage of people dying from health conditions…

Meeting NewsVideo

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology. The…

FDA News

FDA rejects Coherus application for proposed biosimilar to Neulasta

June 12, 2017
The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim. Like…

More Headlines »
Advertisement
Advertisement